Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the ...
Candel Therapeutics Inc. shares gained momentum as Wall Street analysts highlighted the potential of its lead cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback